This was the stock's second consecutive day of losses.
Truist Financial analyst Joon Lee maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback